Gallen Consensus classification, 30.6% of patients had triple-negative BC (TNBC), 33.1% were diagnosed with luminal A, 33.3% with luminal B, and 3% with HER2-positive BC subtype (Figure 1C). Here, ERBB2 is linked to breast cancer.